Breakup! Vland Biotech and Evonik Part Ways as GHS Joint Venture Falls Short of Expectations

On July 31, 2025, Vland Biotech (Qingdao Vland Biotech Co., Ltd.) issued an announcement that drew significant market attention. The notice stated that its wholly-owned subsidiary, Shandong Vland Biotech Co., Ltd., had reached a settlement agreement with Evonik (China) Investment Co., Ltd., and both parties had agreed to dissolve and liquidate their joint venture, Evonik Vland Biotech (Shandong) Co., Ltd., along with its Qingdao branch.

This decision marks the end of the two companies’ joint venture in the field of glutathione (GHS) bioproducts and provides new insights into Sino-foreign joint venture models for the biotech industry.

A Look Back: From Partnership to Parting Ways

In October 2023, Shandong Vland and Evonik China signed a shareholder agreement to jointly invest RMB 37.5 million in a new joint venture. Under the original plan, Shandong Vland held a 45% stake and was responsible for production, while Evonik China held 55% and focused on market development. The joint venture was established in Huimin County, Binzhou, Shandong Province, aiming to leverage the complementary advantages of both parties in biotechnology.

However, the venture was terminated in less than two years. Vland Biotech’s 2024 annual report revealed that the joint venture generated RMB 32.93 million in revenue but suffered a net loss of RMB 6.48 million, falling significantly short of expectations. This performance prompted both sides to reassess the value of the collaboration.

A “Peaceful Breakup” Driven by Multiple Factors
Industry experts believe the decision to end the partnership resulted from a mix of challenges:

Market Uncertainties

Although GHS products have promising applications in feed additives and biomedicine, market cultivation is taking longer than expected. This created a gap between actual results and the joint venture’s short-term performance goals.

Limitations of the Joint Venture Model

The operational structure placed full responsibility for production on Vland, while Evonik China led the market side. This division created coordination inefficiencies. In Q3 2024, an expansion of production lines was planned but ultimately suspended due to Evonik’s tightened investment in China—driven by the EU’s biotech localization policy. This highlighted governance and decision-making bottlenecks within the joint venture. As stated in the announcement, the termination of the original Shareholders' Agreement and OEM Agreement reflects a need to overhaul the cooperation framework.

Shift in Strategic Priorities

Both companies have since adjusted their business focus. Evonik has pivoted toward pharmaceutical-grade GHS, announcing in 2025 that it would shift China-based resources toward drug delivery materials, with feed additives now considered “non-core.” Meanwhile, Vland is advancing its own brand strategy. In 2024, it launched the “Vland Health” sub-brand to serve the domestic animal health market directly—creating direct competition with the joint venture.

Notably, the two parties showed professionalism in handling intellectual property matters. All relevant patents, technologies, and microbial strains will be returned to Vland Biotech free of charge, ensuring protection of core technology assets and preserving potential future cooperation opportunities.

Future Outlook: New Collaboration Model

Although the joint venture is being dissolved, the business relationship between the two parties is not completely severed. According to the agreement, Vland Biotech will continue to provide OEM production services of GHS products to Evonik. This marks a shift from deep capital-based cooperation to a more flexible, business-oriented collaboration.

For Vland Biotech, this move reflects a strategic pivot. As a leading Chinese biotech company with end-to-end capabilities in R&D and manufacturing, this restructuring allows Vland to chart its own path in GHS development while maintaining international business ties.

Industry Insight: Joint Ventures Aren’t the Only Path

While joint ventures remain a common form of cross-border collaboration, they are not universally applicable. In technology-intensive fields, companies must choose the cooperation model that best fits their needs. Vland Biotech’s choice illustrates the growing maturity of Chinese biotech firms: open to global cooperation, but also capable of making timely strategic adjustments.

In a field like biotechnology that requires long-term investment, flexibility in strategy often outweighs rigid adherence to a specific collaboration model. As Chinese biotech capabilities continue to grow, similar cases of realignment may become increasingly common. What matters is whether companies can retain their core strengths and achieve sustainable growth amid changing conditions.

For both Vland Biotech and Evonik China, this “breakup” may in fact be the first step toward discovering a more suitable path for future cooperation.